Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Novocure.

Community Practice Connections™: Overcoming Clinical Inertia in Glioblastoma Multiforme: The Experts Weigh-In on Recent Data Sets and Next Steps to Move the Field Forward

Release Date: December 21, 2018
Expiration Date: December 21, 2019
Media: Internet - based

Activity Overview

Although there have been recent advancements in the understanding of the pathophysiology of glioblastoma multiforme (GBM), as well as modest improvements in its treatment, the overall prognosis for patients with GBM remains poor. While clinical interest in new treatment options to help improve outcomes for these patients is high, the development and incorporation of new technologies and targeted therapies into the treatment paradigm historically has been challenging.

In order to help you increase your understanding of these challenges and provide you with insights into the potential of new technologies—such as Tumor Treating Fields, and novel approaches that include targeted therapies and immunotherapies—to improve patient outcomes, this Web-based activity has been developed to cover the latest advancements. The perspectives of leading clinical experts on recent data and advancements in clinical trials that may change your clinical practice are interwoven throughout the activity with video interviews. This activity explores the management of patients with GBM in both the newly diagnosed and recurrent settings, giving you the opportunity to assess the opinions of multidisciplinary experts and optimize your approach to challenging, real-world clinical scenarios.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Novocure.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This education program is directed towards radiation oncologists, researchers, and other oncology healthcare professionals interested in the treatment of GBM.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Describe the therapeutic rationale for the use of technology and emerging treatment options in the management of patients with GBM
  2. Evaluate safety and efficacy outcomes from recent clinical trials of treatment for GBM
  3. Develop evidence-based strategies to optimize clinical application of recent data on targeted therapies, immunotherapies, and technology for patients with GBM
  4. Identify challenges associated with the current clinical trials landscape for patients with GBM

Faculty, Staff, and Planners' Disclosures

Faculty

Roger Stupp, MD
Chief of Neuro-oncology in the Department of Neurology
Professor of Neurological Surgery, Medicine (Hematology and Oncology) and Neurology (Neuro-oncology)
Feinberg School of Medicine
Chicago, IL

Disclosures: Other: Spouse is a full-time employee of Novartis (since January 2018), previously with Celgene. None of her activities/product portfolio have a relationship to the content of Dr. Stupp’s presentation.

Erik P. Sulman, MD, PhD
Professor and Vice-Chair of Research
Department of Radiation Oncology
Co-Director, Brain Tumor Center
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY

Disclosures: Grant/Research Support: AbbVie, Novocure; Consultant: AbbVie, Novocure, Merck

Christina Tsien, MD
Professor, Department of Radiation Oncology
Washington University School of Medicine
Co-Medical Director, Gamma Knife Center
Chief, Central Nervous System Service
Director, Clinical Research, Department of Radiation Oncology
Siteman Cancer Center
St. Louis, MO

Disclosures: Speakers Bureau: Varian Medical Systems, Merck, AbbVie, Novocure

Vinai Gondi, MD
Co-Director, Brain & Spine Tumor Center, Northwestern Medicine Cancer Center Warrenville
Director of Research & Education, Northwestern Medicine Chicago Proton Center
Radiation Oncology Consultants
Chicago, IL

Disclosures: No relevant financial relationships with commercial interests to disclose

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Related CME Activites






Become a Member

Forgot Password?
Filter By